News | January 09, 2026
Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The study met its primary endpoint with flying colors
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
